332 related articles for article (PubMed ID: 19753129)
21. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH).
Younossi ZM; Jarrar M; Nugent C; Randhawa M; Afendy M; Stepanova M; Rafiq N; Goodman Z; Chandhoke V; Baranova A
Obes Surg; 2008 Nov; 18(11):1430-7. PubMed ID: 18500507
[TBL] [Abstract][Full Text] [Related]
22. [Adipocytokines and nonalcoholic steatohepatitis].
Lăcătuşu C; Mihai B; Mihai C; Cijevschi-Prelipcean C; Graur M
Rev Med Chir Soc Med Nat Iasi; 2009; 113(2):345-52. PubMed ID: 21495339
[TBL] [Abstract][Full Text] [Related]
23. Liver fibrosis in the context of nonalcoholic steatohepatitis: the role of adipokines.
DI Maira G; Pastore M; Marra F
Minerva Gastroenterol Dietol; 2018 Mar; 64(1):39-50. PubMed ID: 28875689
[TBL] [Abstract][Full Text] [Related]
24. The evolving role of leptin and adiponectin in chronic liver diseases.
Tsochatzis E; Papatheodoridis GV; Archimandritis AJ
Am J Gastroenterol; 2006 Nov; 101(11):2629-40. PubMed ID: 16952281
[TBL] [Abstract][Full Text] [Related]
25. [Adipokine and metabolic syndrome].
Zhou LB; Chen MD
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Dec; 28(6):840-4. PubMed ID: 17260479
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia.
Hyogo H; Tazuma S; Arihiro K; Iwamoto K; Nabeshima Y; Inoue M; Ishitobi T; Nonaka M; Chayama K
Metabolism; 2008 Dec; 57(12):1711-8. PubMed ID: 19013295
[TBL] [Abstract][Full Text] [Related]
27. The association between adipocytokines and biomarkers for nonalcoholic fatty liver disease-induced liver injury: a study in the general population.
Zelber-Sagi S; Ratziu V; Zvibel I; Goldiner I; Blendis L; Morali G; Halpern Z; Oren R
Eur J Gastroenterol Hepatol; 2012 Mar; 24(3):262-9. PubMed ID: 22246329
[TBL] [Abstract][Full Text] [Related]
28. Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity.
Tsochatzis E; Papatheodoridis GV; Hadziyannis E; Georgiou A; Kafiri G; Tiniakos DG; Manesis EK; Archimandritis AJ
Scand J Gastroenterol; 2008; 43(9):1128-36. PubMed ID: 18609175
[TBL] [Abstract][Full Text] [Related]
29. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome.
Dietrich P; Hellerbrand C
Best Pract Res Clin Gastroenterol; 2014 Aug; 28(4):637-53. PubMed ID: 25194181
[TBL] [Abstract][Full Text] [Related]
30. Role of adipokines and peroxisome proliferator-activated receptors in nonalcoholic fatty liver disease.
Giby VG; Ajith TA
World J Hepatol; 2014 Aug; 6(8):570-9. PubMed ID: 25232450
[TBL] [Abstract][Full Text] [Related]
31. Beyond insulin resistance in NASH: TNF-alpha or adiponectin?
Hui JM; Hodge A; Farrell GC; Kench JG; Kriketos A; George J
Hepatology; 2004 Jul; 40(1):46-54. PubMed ID: 15239085
[TBL] [Abstract][Full Text] [Related]
32. Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis.
Yang B; Lu L; Zhou D; Fan W; Barbier-Torres L; Steggerda J; Yang H; Yang X
Front Endocrinol (Lausanne); 2022; 13():1007944. PubMed ID: 36267567
[TBL] [Abstract][Full Text] [Related]
33. Adipokines and insulin resistance.
Rabe K; Lehrke M; Parhofer KG; Broedl UC
Mol Med; 2008; 14(11-12):741-51. PubMed ID: 19009016
[TBL] [Abstract][Full Text] [Related]
34. Markers in nonalcoholic steatohepatitis.
Armutcu F; Akyol S; Ucar F; Erdogan S; Akyol O
Adv Clin Chem; 2013; 61():67-125. PubMed ID: 24015600
[TBL] [Abstract][Full Text] [Related]
35. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome.
Kim CH; Younossi ZM
Cleve Clin J Med; 2008 Oct; 75(10):721-8. PubMed ID: 18939388
[TBL] [Abstract][Full Text] [Related]
36. Serum adiponectin, leptin, resistin and RBP4 levels in obese and metabolic syndrome children with nonalcoholic fatty liver disease.
Boyraz M; Cekmez F; Karaoglu A; Cinaz P; Durak M; Bideci A
Biomark Med; 2013 Oct; 7(5):737-45. PubMed ID: 24044566
[TBL] [Abstract][Full Text] [Related]
37. Current treatment strategies for non-alcoholic fatty liver disease (NAFLD).
Mishra P; Younossi ZM
Curr Drug Discov Technol; 2007 Aug; 4(2):133-40. PubMed ID: 17691915
[TBL] [Abstract][Full Text] [Related]
38. How adiponectin, leptin, and ghrelin orchestrate together and correlate with the severity of nonalcoholic fatty liver disease.
Machado MV; Coutinho J; Carepa F; Costa A; Proença H; Cortez-Pinto H
Eur J Gastroenterol Hepatol; 2012 Oct; 24(10):1166-72. PubMed ID: 22735605
[TBL] [Abstract][Full Text] [Related]
39. Irisin in patients with nonalcoholic fatty liver disease.
Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
[TBL] [Abstract][Full Text] [Related]
40. Adipose tissue and its relation to inflammation: the role of adipokines.
Axelsson J; Heimbürger O; Lindholm B; Stenvinkel P
J Ren Nutr; 2005 Jan; 15(1):131-6. PubMed ID: 15648022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
